Remove Clinical Trials Remove Doctors Remove Medicine Remove Pharma Companies
article thumbnail

Edelman Trust Barometer raises questions

World of DTC Marketing

But do doctors trust the system? consumers’ trust in pharma is low, despite the industry’s contributions to ending the pandemic: Only 15% of U.S. consumers say they trust pharma companies more than they did before the COVID-19 pandemic, according to Accenture’s 2021 survey.

article thumbnail

Medical affairs in a digital-first world: Benefits and challenges

Pharmaceutical Technology

The pharmaceutical community has reached somewhat of a turning point as it commercialises a growing number of speciality medicines relying on complex new treatment pathways. Nowadays, it is an active choice many pharma companies and service providers are taking. A fresh approach.

Medicine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Frontiers Health Steering Committee spotlight – Paul Tunnah

pharmaphorum

So, historically – certainly pre-2000 – if you look at the way prescription drugs were communicated, it was very tightly controlled: it was pharma companies speaking to doctors and the doctor would speak to the patient and tell them what they thought the right solution was,” he said.

article thumbnail

Team behind RECOVERY trial of COVID drugs casts its net wider

pharmaphorum

The UK scientists that ran one of the largest trials of experimental COVID-19 drugs have formed a non-profit company that will apply the methodology to other disease areas – with $6.8 ” Those trials also need to be large, involve a diverse range of individuals, and able to be run at reduced cost, said Landray.

Trials 77
article thumbnail

Be in the room: Turning patient engagement to patient centricity

pharmaphorum

The avid blogger and passionate advocate retired from his R&D role four years ago to focus on his own health, and now works full time on making sure the patient voice is “in the room” when pharma companies make decisions. Winding road. “My At that time, the five-year survival rate was in the order of 7%. Levelling up.

article thumbnail

Real Chemistry Introduces IRIS, an Information Hub for All Things GLP-1 Drugs

XTalks

According to Real Chemistry, there are currently 119 active GLP-1 agonist clinical trials, with 53 in Phases III or IV, across more than 60 potential new indications for GLP-1 treatment.

Drugs 52
article thumbnail

From patient engagement to patient centricity

pharmaphorum

Dialogue requires humility on the drug company’s side—accepting that sometimes we are wrong about matters we think we understand—and trust on the patients’ side that representatives of large, for-profit entities really have come to listen. When that happens, outcomes will change.